Home

Sanofi - American Depositary Shares (SNY)

48.75
+0.00 (0.00%)
NASDAQ · Last Trade: Jul 23rd, 5:01 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close48.75
Open-
Bid49.47
Ask49.50
Day's RangeN/A - N/A
52 Week Range45.80 - 60.12
Volume3,078
Market Cap60.97B
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield2.212 (4.54%)
1 Month Average Volume1,811,084

Chart

About Sanofi - American Depositary Shares (SNY)

Sanofi-Aventis is a global healthcare company dedicated to improving health and well-being through the development and production of a wide range of pharmaceutical products and vaccines. With a strong focus on research and innovation, the company operates in various therapeutic areas, including diabetes, oncology, cardiovascular disease, central nervous system disorders, immunology, and rare diseases. Sanofi-Aventis also emphasizes the importance of vaccines in disease prevention and offers a portfolio that addresses public health needs. The company strives to enhance patients' quality of life by providing effective treatments and advancing healthcare solutions worldwide. Read More

News & Press Releases

Humana Moves To Cut Prior Authorization Delays, Streamline Care Approvalsbenzinga.com
Humana will cut prior authorizations, launch a gold card program, and speed up electronic approvals to improve care access and transparency by 2026.
Via Benzinga · July 22, 2025
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To USbenzinga.com
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
Via Benzinga · July 22, 2025
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buybenzinga.com
Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.
Via Benzinga · July 22, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   
By Pomerantz LLP · Via GlobeNewswire · July 18, 2025
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adultsbenzinga.com
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.
Via Benzinga · July 15, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sanofi - SNY
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   
By Pomerantz LLP · Via GlobeNewswire · July 14, 2025
Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimonybenzinga.com
Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal standards by the trial judge.
Via Benzinga · July 11, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   
By Pomerantz LLP · Via GlobeNewswire · July 10, 2025
Dow Futures Edge Up As Trump Prepares More Tariff Letters: Freeport, UnitedHealth, Meta, Novo Nordisk, AstraZeneca Among Stocks In Focusstocktwits.com
While Dow Jones futures edged up by 0.17% at the time of writing, the S&P 500 futures were up 0.15%.
Via Stocktwits · July 9, 2025
Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analystbenzinga.com
Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end of 2025.
Via Benzinga · July 8, 2025
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shotinvestors.com
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot.
Via Investor's Business Daily · July 7, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   
By Pomerantz LLP · Via GlobeNewswire · July 6, 2025
Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myelomabenzinga.com
FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.
Via Benzinga · July 3, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 1, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
NEW YORK CITY, NY / ACCESS Newswire / June 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Via ACCESS Newswire · June 30, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   
By Pomerantz LLP · Via GlobeNewswire · June 28, 2025
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.
Via MarketBeat · June 28, 2025
Why This Biotech Stock Just Doubled In A Single Daybenzinga.com
Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition.
Via Benzinga · June 26, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
NEW YORK CITY, NY / ACCESS Newswire / June 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Via ACCESS Newswire · June 26, 2025
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?benzinga.com
Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.
Via Benzinga · June 25, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
NEW YORK CITY, NY / ACCESS Newswire / June 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Via ACCESS Newswire · June 25, 2025
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapiesbenzinga.com
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.
Via Benzinga · June 25, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
NEW YORK CITY, NY / ACCESS Newswire / June 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Via ACCESS Newswire · June 24, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   
By Pomerantz LLP · Via GlobeNewswire · June 23, 2025
Why Is Cidara Therapeutics Stock Trading Higher On Monday?benzinga.com
Cidara's CD388 met key goals in a Phase 2b flu trial, showing strong efficacy and safety data, with FDA talks planned for advancing to Phase 3.
Via Benzinga · June 23, 2025